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while Tumour Necrosis-α-like Weak inducer of Apoptosis (TWEAK) and
interferon-β were increased over17d. No changes occurred in expression of
mRNA for RANK, NFATc1, OSCAR or cathepsin-K.
Conclusions: The results show that bone resorption is inhibited by OST
and its component RNAs in a concentrated-related manner. The inhibitory
effects may possibly relate to events downstream of NFATc1 regulation.
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THE CINOD NCX 429 EXERTS ANTI-INFLAMMATORY EFFECTS IN ISOLATED
HUMANMONOCYTES AND MACROPHAGES
A. Amoruso1, D. Federici Canova1, L.G. Fresu1, J. Padron2, E. Ongini2,
S. Brunelleschi1
1Dept Med. Sci., Univ. of Piemonte Orientale "A. Avogadro", Novara, Italy;
2Nicox Res. Inst., Bresso, Milan, Italy
Purpose: Cyclooxygenase-inhibiting nitric oxide donators (CINODs) repre-
sent a new class of anti-inﬂammatory drugs designed to provide the anti-
inﬂammatory effects of non steroidal anti-inﬂammatory drugs (NSAIDs)
while donating nitric oxide (NO) with the aim of mitigating side-effects
in the gastrointestinal and cardiovascular systems. CINODs exercise their
analgesic and anti-inﬂammatory effects via cyclooxygenase (COX) inhibi-
tion, and exhibit an improved tolerability, via the protective action of nitric
oxide (NO) on gastric mucosa and vascular function. We have assessed the
effect of NCX 429, a naproxen-based CINOD, on human monocytes and
monocyte-derived macrophages (MDM) isolated from healthy volunteers,
in comparison with naproxen.
Methods: Human monocytes were isolated from heparinised venous blood
of healthy donors by standard techniques in Hystopaque gradient centrifu-
gation (400×g, 30 min, room temperature) and recovered by thin suction
at the interface. MDM were prepared from monocytes, by culture (8-10
days) in RPMI 1640 medium containing 20% FBS.
Cells (1×106) were pre-treated for 1 h with NCX 429 or naproxen (1 nM
- 100 μM) and then stimulated with 0.1 μM phorbol myristate acetate
(PMA) for 24 h. Supernatant was collected at the end of the incubation for
measurement of IL-6 release (ELISA).
To evaluate superoxide anion (O–2) production, human monocytes (1×106
cells/plate) were stimulated with PMA (1 μM, 30 min) in the absence
or presence of NCX 429 or naproxen. O–2 production was evaluated by
the superoxide dismutase (SOD)-inhibitable cytochrome C reduction and
expressed as nmol cytochrome C reduced/106 cells/30 min. The MMP-9
activity was evaluated by gelatin zymography.
Results: NCX 429 in the range 1 nM - 100 μM inhibited PMA-induced IL-6
release in monocytes in a concentration dependent mode (IC50 = 870 nM);
at the maximal concentration, the inhibition by NCX 429 reached 62±8%,
signiﬁcantly higher than the inhibition afforded by naproxen (36±4%,
p<0.05, n=7). In MDM, 100 μM NCX 429 inhibited by 52±11% (n=5) PMA-
induced IL-6 release, while naproxen had no effect. A stronger effect of NCX
429 was also observed by evaluating superoxide production in monocytes
and MDM. At 1 μM, NCX 429 inhibited PMA-induced O–2 production by
about 24% in monocytes and 60% in MDM (n =6), whereas naproxen
produced little or no effect. Moreover, NCX 429 reduced PMA-induced O–2
production in monocytes isolated from patients affected by rheumatoid
arthritis (n=3). Interestingly, NCX 429, but not naproxen, signiﬁcantly
inhibited matrix metalloproteinase (MMP)-9 activity in lipopolysaccharide
(LPS)-challenged monocytes from healthy volunteers (p<0.05 vs LPS, n=3).
Conclusions: These results show additional anti-inﬂammatory effects of
NCX 429 with respect to the reference NSAID, naproxen. CINODs, through
NO donation, have been shown to have a favourable blood pressure and
gastrointestinal proﬁle relative to available NSAIDs in animal models; the
present data suggest that NO donation from CINODs might also account
for further anti-inﬂammatory effects beside the ones dependent on COX
inhibition.
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NAPROXCINOD, UNLIKE NAPROXEN, INHIBITS EXPRESSION OF iNOS IN
ACTIVATED MACROPHAGES IN VITRO
D. Ronchetti, E. Bastia, D. Miglietta, J. Padron
Nicox Res. Inst. Srl, Bresso, Milan, Italy
Purpose: Macrophages play a pivotal role in several inﬂammatory diseases
and represent a valuable model for studying anti-inﬂammatory proper-
ties of new drugs. Activated macrophages produce and release numerous
inﬂammatory mediators including cytokines, prostaglandins and reactive
oxygen and nitrogen species. At physiologic concentrations, nitric oxide
(NO) inhibits the expression and activity of pro-inﬂammatory mediators,
whereas at high concentrations (i.e., during inﬂammation) it induces cy-
tokine expression and tissue damage. Naproxcinod is the ﬁrst-in-class
cyclooxygenase inhibiting nitric oxide donator (CINOD), designed to exert
effective anti-inﬂammatory actions through cyclooxygenase (COX) inhibi-
tion while releasing NO, with the aim of mitigating NSAIDs-associated
unwanted effects. The purpose of this study was to characterize COX-
inhibiting and NO-donating properties of the CINODs naproxcinod and NCX
429, and to investigate whether they modulate the expression of inducible
nitric oxide synthase (iNOS) in activated macrophages differently from a
reference NSAID, naproxen.
Methods: NO release was evaluated by assessing vascular tone on isolated
rabbit aortic rings pre-contracted with methoxamine (3 μM) was recorded
after incubation with vehicle or test compounds (0.01-100 μM) in the
presence or absence of the soluble guanylyl cyclase (sCG) inhibitor ODQ
(1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, 10 μM).
To assess COX-1 inhibition, RAW 264.7 murine macrophages were incu-
bated with test compounds (0.01-100 μM, 30 minutes) and stimulated
with arachidonic acid (1 μM, 15 min). To assess COX-2 inhibition, aspirin
(100 μM) pretreated cells were incubated with 1 μg/ml LPS and 10 ng/ml
IFNγ.for 16 h to induce COX-2 expression and then treated as above. Es-
terases (1.67 U/sample) were added to accelerate naproxcinod metabolism.
Supernatant was collected for enzymatic immuno-assay of PGE2.
In different experiments, cells were incubated overnight with LPS (1 μg/ml)
and IFNγ (10ng/ml) in the presence of vehicle or test compounds (0.1-100
μM) and nitrites quantiﬁed in the supernatant by the Griess reaction. Cells
were lysed for Western blot and iNOS quantiﬁed by chemiluminescence.
Results: Naproxcinod and naproxen showed similar in vitro inhibition of
COX-1 and COX-2 (COX-1 IC50= 3.0±1.3 and 8.1±5.8 μM, respectively;
COX-2 IC50= 3.9±1.7 and 10.4±8.4 μM, respectively). Additionally, naprox-
cinod and NCX 429, but not naproxen, were able to induce relaxation of
pre-contracted rabbit aortas (EC50=5.5±1.7 and 6.2±1.6 μM, respectively),
similarly to isosorbidemononitrate (EC50=10.8±2.4 μM). The vasorelaxation
was mediated by activation of the NO-signaling pathway, as prevented by
the sGC inhibitor ODQ.
Interestingly, in activated RAW 264.7 macrophages, naproxcinod and NCX
429 (IC50=0.8μM) but not naproxen inhibited LPS/IFNγ-mediated increase
in nitrite concentrations. Consistently, naproxcinod reduced iNOS protein
expression, whereas naproxen was ineffective.
Conclusions: The CINODs naproxcinod and NCX 429 inhibit expression
of iNOS in activated macrophages in vitro, likely through a mechanism
involving donation of NO. Therefore, in addition to the reported differenti-
ated blood pressure and gastrointestinal proﬁle over available NSAIDs, NO
release from CINODs might confer additional anti-inﬂammatory properties.
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KNEE OSTEOARTHRITIS: SAFETY AND EFFICACY OF CLODRONATE IV
M. Scarpellini, A. Lurati, M. Marrazza, K. Re, D. Bompane
Magenta Hosp., Magenta, Italy
Purpose: To assess the clinical effects of intravenous courses of clodronate
in established knee osteoarthritis (OA) resistant to common treatment with
non-steroidal anti-inﬂammatory drugs or local corticosteroids
Methods: Subjects aged 40 to 80 years with knee OA, from moderate to
severe, were enrolled. The patients were treated with a 10 days course
of clodronate i.v. 300mg/die every 3-6 months for 1 year. Patients were
followed-up every 3 months. At each visit, pain scores (100 mm visual
analogue scale [VAS]), Lequesne index scores, NSAID intake, physician and
patient global assessments scores were recorded. Adverse events (AEs)
were recorded throughout the study.
Results: 122 patients (females 107, males 15; mean age 74.3±5.1, Kellgren-
Lawrence grade II or III OA) were enrolled. Statistically signiﬁcant re-
ductions in VAS pain scores, Lequesne index scores and NSAID usage
were reported at all time-points (baseline VAS 67.02±10.4, 1 month VAS
46.5±15.3, 6 months VAS 41.7±11.3, 12 months 37.2±4.3 p<0.01). No
systemic, serious or severe side effects were observed.
Conclusions: This study supports the safety, tolerability and effectiveness
of Clodronate in the treatment of symptomatic knee OA. Clodronate may
also offer economic beneﬁts due to a reduction in NSAID usage and the
resultant reduction in management costs of NSAID related side-effects. This
